Clinical Trials Logo

PR-Positive Breast Cancer clinical trials

View clinical trials related to PR-Positive Breast Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04901299 Withdrawn - Clinical trials for Metastatic Breast Cancer

Fulvestrant + Neratinib In Breast Cancer

HER2-Signal
Start date: July 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2 open label, multi-center non-randomized interventional study designed to evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously treated metastatic HR-positive, HER2-negative breast cancer. - This research study involves the study drug Neratinib - The standard of care drug Fulvestrant